Remdesivir Derivative VV116 Is a Potential Broad-Spectrum Inhibitor of Both Human and Animal Coronaviruses
Viruses · 23.11.2023 · 15 (12) · 2295
DOI: 10.3390/v15122295 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, online erschienen am 23.11.2023. Verfasst von Weiyong Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Hauptthemen laut MEDLINE: Coronavirus 229E, Human, Coronavirus OC43, Human, Coronavirus NL63, Human. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
Coronaviruses represent a significant threat to both human and animal health, encompassing a range of pathogenic strains responsible for illnesses, from the common cold to more severe diseases. VV116 is a deuterated derivative of Remdesivir with oral bioavailability that was found to potently inhibit SARS-CoV-2. In this work, we investigated the broad-spectrum antiviral activity of VV116 against a variety of human and animal coronaviruses. We examined the inhibitory effects of VV116 on the replication of the human coronaviruses HCoV-NL63, HCoV-229E, and HCoV-OC43, as well as the animal coronaviruses MHV, FIPV, FECV, and CCoV. The findings reveal that VV116 effectively inhibits viral replication across these strains without exhibiting cytotoxicity, indicating its potential for safe therapeutic use. Based on the results of a time-of-addition assay and an rNTP competitive inhibition assay, it is speculated that the inhibitory mechanism of VV116 against HCoV-NL63 is consistent with its inhibition of SARS-CoV-2. Our work presents VV116 as a promising candidate for broad-spectrum anti-coronavirus therapy, with implications for both human and animal health, and supports the expansion of its therapeutic applications as backed by detailed experimental data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- Department of Emergency Medicine, The Third People's Hospital of Hubei Province, Wuhan 430033, China.
- State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China.
ORCID-Profile: Qi Zhang
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Liu, W., Zhang, M., Hu, C., Song, H., Mei, Y., Liu, Y., & Zhang, Q. (2023). Remdesivir Derivative VV116 Is a Potential Broad-Spectrum Inhibitor of Both Human and Animal Coronaviruses. Viruses, 15(12), 2295. https://doi.org/10.3390/v15122295
Vancouver
Liu W, Zhang M, Hu C, Song H, Mei Y, Liu Y, et al. Remdesivir Derivative VV116 Is a Potential Broad-Spectrum Inhibitor of Both Human and Animal Coronaviruses. Viruses. 2023;15(12):2295. doi:10.3390/v15122295
BibTeX
@article{Liu2023,
author = {Liu, Weiyong and Zhang, Min and Hu, Chengxiu and Song, Huijuan and Mei, Yi and Liu, Yingle and Zhang, Qi},
title = {Remdesivir Derivative VV116 Is a Potential Broad-Spectrum Inhibitor of Both Human and Animal Coronaviruses},
journal = {Viruses},
year = {2023},
volume = {15},
number = {12},
pages = {2295},
doi = {10.3390/v15122295}
}
EUVIMED